非布索坦
医学
高尿酸血症
血压
内科学
黄嘌呤氧化酶抑制剂
随机对照试验
尿酸
黄嘌呤氧化酶
生物化学
酶
化学
作者
Yuichi Saito,Atsushi Tanaka,Yoshio Koide,Haruhiko Yoshida,Daigaku Uchida,Kazuo Matsunaga,Naoto Yokota,Chikara Ueyama,Yoshio Kobayashi,Koichi Node
出处
期刊:RMD Open
[BMJ]
日期:2022-09-01
卷期号:8 (2): e002505-e002505
标识
DOI:10.1136/rmdopen-2022-002505
摘要
Objectives Although uric acid lowering therapies, including xanthine oxidase (XO) inhibition, may reduce the absolute level of blood pressure (BP), the effect of XO inhibition on BP variability is largely unknown. The aim of the present analysis was to evaluate the impact of febuxostat, an XO inhibitor, on BP variability in a randomised trial setting. Methods This was a subanalysis of the PRIZE Study, a randomised trial to evaluate the potential effect of febuxostat on carotid intima–media thickness progression. Patients with hyperuricemia and carotid plaques were randomly assigned to the febuxostat or control group. During a 24-month period, office BP and pulse rate (PR) were measured ≥3 times. BP and PR variabilities were assessed with SD and coefficient of variation (CV). The effect of febuxostat on BP and PR variabilities was adjusted with age, sex and baseline BP or PR, expressed with 95% CIs. Results A total of 472 patients were included into the present subanalysis. During the 24-month follow-up period, the febuxostat group had a significantly lower adjusted mean systolic BP (128.4 (126.8–130.0) vs 130.7 (129.1–132.2) mm Hg, p=0.04) and CV of systolic BP (7.4 (6.7–8.0) vs 8.2 (7.6–8.8), p=0.04) than the control group. Adjusted SD of PR was also lower in the febuxostat group than their counterpart (5.95 (4.93–6.97) vs 7.33 (6.32–8.33), p=0.04). Conclusion XO inhibition with febuxostat was associated with reduced visit-to-visit BP variability as well as reduced PR variability in patients with hyperuricemia and carotid plaques. Trial registration numbers University Hospital Medical Information Network Clinical Trial Registry (UMIN000012911 and UMIN000041322).
科研通智能强力驱动
Strongly Powered by AbleSci AI